Loading
A phase 3 trial of Cabergoline in Pituitary tumours, run by University of Sao Paulo General Hospital, completed.
Cabergoline in Nonfunctioning Pituitary Adenomas is a phase 3 interventional study registered as NCT03271918 by University of Sao Paulo General Hospital, with 140 participants recorded, started 2015-02-01 and reaching its primary completion in 2017-02-01. Interventions recorded: Cabergoline. Conditions recorded: Pituitary Adenoma, Nonfunctioning Pituitary Adenoma.
Linked to the drug Cabergoline because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.
Shares Cabergoline, Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Cabergoline, Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.